Most VEXAS pts have pulm involvement on HRCT. Pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement. Abs 1569 #ACR22 @RheumNow https://t.co/7AB3b9e7Lt https://t.co/ikhQMEu5GA

• Lung Involvement in VEXAS Syndrome - ACR Meeting Abstracts

Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY

• Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phas…

Does lifestyle impact Tx. response? #Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA - The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi - Important to discuss lifestyle when starting tx. @RheumNow #ACR22 https://t.co/z98DFMLxu3

Refractory cystoid macular edema assoc'd w/ Bechet's uveitis can be effectively treated either with ADA, IFX or TCZ. Abs 1564 #ACR22 @RheumNow https://t.co/WcEI4d0Cl5 https://t.co/Tk0T41coog

• Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involveme…

ACR2022 Topic Panels https://t.co/0cto8DE7P5

• https://twitter.com/i/broadcasts/1rmxPkwQjyMJN

Industry Abstract Previews of #ACR22 The pharmaceutical companies will showcase their featured clinical trials and abstracts at #ACR22. These are their best studies for you to review and evaluate as part of your to-do list. https://t.co/8fBJmT1cXG https://t.co/r7H5sqELPo

• https://bit.ly/3NZtKLb

Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd

• Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and Firs…

ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN

• Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Densi…

#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort - identified 5 clusters based on comorbidity - Depression cluster --> ↑ disease activity and fxnl impairment @RheumNow #ACR22 https://t.co/cGz4vpOGJ9

Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf

• Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on B…

Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm

• Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results…

PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ

• Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk …

In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

• Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…